Sensei biotherapeutics provides corporate update and highlights key upcoming milestones

- completed sns-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - expands patient cohort in specific tumor types - - multiple clinical milestones expected in 2024 - - strong balance sheet with cash runway extended into the fourth quarter of 2025 - boston, jan. 04, 2024 (globe newswire) --  sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones. “in 2023, we significantly advanced our lead clinical asset while prudently maintaining our strong balance sheet,” said john celebi, president and chief executive officer.
SNSE Ratings Summary
SNSE Quant Ranking